At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.

Several new device-based therapies are emerging designed to fill the treatment gap for migraine suffers who do not respond to traditional migraine therapies. These novel treatments include a headband-like device designed to stimulate the trigeminal nerve and an image-guided intranasal interventional treatment.

Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.